Literature DB >> 17295818

Outcomes after oesophagogastrectomy for carcinoma of the oesophagus.

Mark Omundsen1, Richard Babor, Peter Johnston.   

Abstract

BACKGROUND: Carcinoma of the oesophagus is a rare but a highly lethal malignancy. The incidence of adenocarcinoma in particular is increasing in the Western world. Despite improvements in staging, perioperative care and the use of adjuvant/neoadjuvant regimen the prognosis remains poor.
METHODS: All patients who had biopsy-proven oesophageal carcinoma between the years 1992 and 2004 in the Wellington region, New Zealand, were retrospectively reviewed. The personal and tumour characteristics, operation details, complications and the details of hospital stay of patients who had had a resection were recorded in a database . Survival data were recovered from the notes, hospital database or general practitioner records and were available for all patients who had surgery. Survival analyses were calculated using Kaplan-Meier estimates.
RESULTS: One hundred and ninety-one patients were diagnosed with oesophageal carcinoma during the study period (59% adenocarcinoma, 32% squamous cell carcinoma). Only 35% (n = 67) had a resection (81% adenocarcinoma, 13% squamous cell carcinoma). Fifty-one (77%) had an Ivor Lewis procedure, 9 (14%) had only a laparotomy and 6 (9%) had a laparotomy, right thoracotomy and cervical incision. Forty-six (70%) tumours were in the distal third of the oesophagus and 13 (20%) were at the oesophagogastric junction. Perioperative mortality was 10% (n = 7) and anastomotic leak rate 9% (n = 6). Five-year survival was 23%.
CONCLUSION: Results from our institution for the resection of oesophageal cancer compare favourably with those in the published work. Staging with computed tomography and laparoscopy has resulted in acceptable resection and survival rates. Survival for this disease is still largely stage dependent and earlier diagnosis probably holds the key to improved prognosis.

Entities:  

Mesh:

Year:  2007        PMID: 17295818     DOI: 10.1111/j.1445-2197.2006.03973.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  1 in total

1.  Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.

Authors:  Jorge-Shmuel Delgado; Reba Mustafi; Jason Yee; Sonia Cerda; Anusara Chumsangsri; Urszula Dougherty; Lev Lichtenstein; Alessandro Fichera; Marc Bissonnette
Journal:  Dig Dis Sci       Date:  2008-05-30       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.